Helus Pharma Inc.(HELP)

Medical - Pharmaceuticals · Toronto, ON

$10.76-0.66 (-5.78%)

Delayed quote: Oct 6, 2026, 10:55 AM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T14:57:12.373Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:57:12.373Z.

Quote observation: 2026-10-06T14:55:29.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 10.76
Unrounded diluted TTM EPS · period ending 2026-06-30: -5.51

FMP input reference: 934548bd97ab8c390298f716fcf622fc2d1107cfab085c47b2b47650fd31fbc6

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

HELP PE Ratio Metrics

PE RATIO

N/A

HELP Competitors' PE Ratio

HELP

Helus Pharma Inc.

Current

Market Cap

$666.95M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FDMT

4D Molecular Therapeutics, Inc.

vs HELP

Market Cap

$665.48M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDXG

MiMedx Group, Inc.

vs HELP

Market Cap

$665.40M

PE Ratio

114.13

TTM Avg

37.43

3Y Avg

206.22

5Y Avg

206.22

ANNX

Annexon, Inc.

vs HELP

Market Cap

$679.13M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OABI

OmniAb, Inc.

vs HELP

Market Cap

$643.45M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AURA

Aura Biosciences, Inc.

vs HELP

Market Cap

$640.57M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVR

Anteris Technologies Global Corp.

vs HELP

Market Cap

$695.21M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLYM

Climb Bio, Inc.

vs HELP

Market Cap

$637.34M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FTH

Faeth Therapeutics, Inc.

vs HELP

Market Cap

$704.02M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OLMA

Olema Pharmaceuticals, Inc.

vs HELP

Market Cap

$707.95M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Helus Pharma Inc. (HELP)	$666.95M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$665.48M	N/A	N/A	N/A	N/A
MiMedx Group, Inc. (MDXG)vs ›	$665.40M	114.13	37.43	206.22	206.22
Annexon, Inc. (ANNX)vs ›	$679.13M	N/A	N/A	N/A	N/A
OmniAb, Inc. (OABI)vs ›	$643.45M	N/A	N/A	N/A	N/A
Aura Biosciences, Inc. (AURA)vs ›	$640.57M	N/A	N/A	N/A	N/A
Anteris Technologies Global Corp. (AVR)vs ›	$695.21M	N/A	N/A	N/A	N/A
Climb Bio, Inc. (CLYM)vs ›	$637.34M	N/A	N/A	N/A	N/A
Faeth Therapeutics, Inc. (FTH)vs ›	$704.02M	N/A	N/A	N/A	N/A
Olema Pharmaceuticals, Inc. (OLMA)vs ›	$707.95M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

HELP PE Ratio Metrics

HELP Competitors' PE Ratio

P/E Comparison

PE Ratio Formula & Definition

Related Metrics